Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
TheBody.com/The Body PRO Covers CROI 2009, February 8-11, 2009
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Isentress Equal to Sustiva in First Line Therapy

February 15, 2009

In a poster presentation at CROI 2009 in Montreal, Canada, the STARTMRK study results show that the first-in-class integrase inhibitor Isentress (raltegravir) works at least as well as Sustiva (efavirenz) at suppressing HIV levels. It also showed that using Isentress resulted in higher CD4 counts.

STARTMRK included 563 people who had never been on HIV therapy. Half received Isentress (400mg, 2x a day) or Sustiva (600m, 1x a day) with Truvada (tenofovir/Viread + emtricitabine/Emtriva). At study entry, none showed resistance to Sustiva or Truvada, all had viral loads above 5,000 with more than half above 100,000, and nearly half had CD4 counts below 200.

The study included 19% women and 58% people of color, while the average age was 37 years. Nearly 1 in 5 had a type of HIV different from subtype B, a common type found in the US. The study assessed the number of people who had undetectable HIV and the rate of change in CD4s. Side effects were also studied, including effects on the central nervous system (CNS) and changes in fats/cholesterol levels (called lipid levels).

Advertisement
After 48 weeks on therapy, Isentress suppressed HIV as well as Sustiva. Isentress increased CD4 counts higher than Sustiva, but it's not clear if this increase was statistically meaningful. Isentress was, in general, better tolerated. Fewer overall side effects occurred with Isentress than Sustiva and notably there were fewer CNS affects with Isentress. As for effects on the liver in those with or without hepatitis B or C, both drugs performed similarly.

Isentress was developed and approved for use in treatment experienced individuals. However, this study is one of many that are looking at its effectiveness when used in first line therapy. Here, compared against the most widely used NNRTI, Isentress seems to be an equal choice for people starting therapy for the first time.

The decision to choose one strategy over the other would likely come down to concerns about side effects. From this and other studies, Isentress seems well tolerated, but since it's a very new drug we don't know its possible side effects over the long-term. On the other hand, Sustiva has been well studied and its effects on the CNS are well documented and have long been a concern for many. These include sleep disturbances, unusual dreams and trouble concentrating as well as rash, dizziness and diarrhea. Some people tolerate Sustiva very well; many others experience at least some degree of side effects which may affect their adherence. At this point, it may just come down to which drug is better tolerated by a given individual and what side effects a person is willing to live with.


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Project Inform. Visit Project Inform's website to find out more about their activities, publications and services.
 
See Also
CROI 2009 Newsroom



Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement